Role of the VEGFR3/VEGFD receptor axis in TGFβ1 activation of primary prostate cell lines

BACKGROUND. Reports indicate that vascular endothelial growth factor receptor type 3 (VEGFR3) regulates cellular functions such as invasion, proliferation, and chemo-resistance. However, the exact function of the VEGFR3 signaling axis in prostate epithelial cells is poorly characterized. METHODS. The goal of this study was to evaluate whether TGFb1 in combination with VEGFD can promote pre-malignant invasive activities of intermediate basal cells (IBC-10a) isolated from human prostate cancer (Gleason score 6). RESULTS. hTERT immortalized IBC-10a cells normally grew as confluent ‘‘cobblestoned’’ monolayers, but treatment with TGFb1 (10 ng/ml for 2–6 hr) dissociated the cell–cell junctions and induced VEGFR3 translocation to the cell surface. This event was not inhibited by 10 mM cycloheximide or puromycin, indicating transcription and protein synthesis were not required. We further discovered that TGFb1 in combination with VEGFD induced a significant increase in the invasive activity of IBC-10a cells (>26% and 53% after 24 and 48 hr, respectively) in modified Boyden Chamber assays. TGFbRII receptor antibodies specifically blocked TGFb1 induction of VEGFR3 translocation to the cell surface and blocked VEGFD-induced invasion. Zymograms revealed that TGFb1 (and not VEGFR3) stimulated the secretion of MMP-2 and MMP-9, presumably to promote cell invasion. The cell invasion assays confirmed that antibodies specific for TGFbII receptor, MMP-2 and MMP-9 and VEGFR3, independently blocked TGFb1-induced invasion. CONCLUSIONS. For the first time, we have demonstrated the mechanism by which TGFb1 stimulates VEGFD/VEGFR3 receptor axis activation leading to increased cell migration and invasion by primary intermediate basal cell cultures. Prostate 69: 982–990, 2009. # 2009 Wiley-Liss, Inc.

[1]  M. Stearns,et al.  Dysplasia of human prostate CD133hi sub‐population in NOD‐SCIDS is blocked by c‐myc anti‐sense , 2009, The Prostate.

[2]  P. Heikkilä,et al.  VEGF-D in association with VEGFR-3 promotes nodal metastasis in human invasive lobular breast cancer. , 2007, American journal of clinical pathology.

[3]  I. Giannopoulou,et al.  Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma. , 2007, European Journal of Surgical Oncology.

[4]  M. Hung,et al.  The role of the VEGF-C/VEGFR-3 axis in cancer progression , 2006, British Journal of Cancer.

[5]  J. Shih,et al.  The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. , 2006, Cancer cell.

[6]  S. Jakowlew Transforming growth factor-beta in cancer and metastasis. , 2006, Cancer metastasis reviews.

[7]  K. Jennbacken,et al.  Expression of vascular endothelial growth factor C (VEGF‐C) and VEGF receptor‐3 in human prostate cancer is associated with regional lymph node metastasis , 2005, The Prostate.

[8]  N. Kyprianou,et al.  Transforming growth factor beta and prostate cancer. , 2005, Cancer treatment and research.

[9]  J. Sleeman,et al.  MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo , 2004, International journal of cancer.

[10]  M. Stearns,et al.  Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4tΔ773–1081 overexpression is diagnostic for sentinel lymph node metastasis , 2004, Laboratory Investigation.

[11]  P. Scardino,et al.  Expression of vascular endothelial growth factor receptor‐3 (VEGFR‐3) in human prostate , 2004, The Prostate.

[12]  J. M. Mullin Epithelial Barriers, Compartmentation, and Cancer , 2004, Science's STKE.

[13]  J. Sleeman,et al.  Expression of vascular endothelial growth factor (VEGF)‐C and VEGF‐D, and their receptor VEGFR‐3, during different stages of cervical carcinogenesis , 2003, The Journal of pathology.

[14]  Michael J. Wilson,et al.  Expression of matrix metalloproteinase‐2 and ‐9 and their inhibitors, tissue inhibitor of metalloproteinase‐1 and ‐2, in primary cultures of human prostatic stromal and epithelial cells * † , 2002, Journal of cellular physiology.

[15]  D. Witte,et al.  Expression of the vascular endothelial growth factor receptor-3 (VEGFR-3) and its ligand VEGF-C in human colorectal adenocarcinoma. , 2002, Anticancer research.

[16]  S. Rafii,et al.  Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. , 2002, Blood.

[17]  Y Sakai,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis , 2022 .

[18]  K. Alitalo,et al.  Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis , 1999, British Journal of Cancer.

[19]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Taipale,et al.  Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion. , 1998, Advances in cancer research.

[21]  M. Stearns,et al.  IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. , 1997, Invasion & metastasis.

[22]  H. Bonkhoff,et al.  Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model , 1996, The Prostate.

[23]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[24]  H. Bonkhoff Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. , 1996, European urology.

[25]  M. Stearns,et al.  IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression. , 1995, Oncology research.

[26]  K. Alitalo,et al.  FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. , 1992, Cancer research.

[27]  D. S. Coffey,et al.  Etiology and disease process of benign prostatic hyperplasia , 1989, The Prostate. Supplement.